Given the high cost (hundreds of millions) of taking a vaccine through clinical trials, FDA approval and production I'm curious why the choice to go the non-profit route. Is the growth plan to raise the money from large donors (Gates foundation, Wellcome Trust, etc.) or to licence the technology to more traditional pharma firms ?
Most of the people who are living w/ HIV worldwide can't afford to pay for treatment. From our perspective it doesn't make sense to charge for something that the people who need it most just can't pay for. By making our project non profit we can focus on the real goal, which is ending HIV/AIDS and not creating ROI for shareholders. Yes we will need to raise significant funding over the lifetime of the project to comp…
Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
41–50 of 135 posts
Re: Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
#42Earlier quoted context omitted.
Exactly. In this case, we're lucky enough to use an amazing clinic set up in Durban, South Africa, which has a ~15% prevalence rate of HIV.
This sounds great. I'm genuinely interested, how is the potential vaccine going to be presented to volunteers in Phase I? And do you also deliver a placebo vaccine for blinding? It seems like believing you are vaccinated would increase risky behaviour. This is bad in itself. It is also bad if the vaccine is only partially effective, since the risk effect might balance the vaccine effect. With a placebo, knowing you o…
Re: Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
#43Does anyone know why this approach is "viewed as a rogue project by the immunology community"? Is it just because it's new, or is there something more fundamental that conflicts with established immunology?
Hi all, this is Naveen from Immunity Project YC team. The fact that we are using ML to identify epitopes that are the preferred targets on the virus for HIV controllers is key to what makes our project unique. This is a newer approach for developing a vaccine and therefore makes it "rogue."
Sometimes thinking out of the box and letting go of established ways will lead to results.
Edit: Also in computer sciences we use differentiating between two known states to find out how to change on state to the other one perfectly. In immunology do you use similar approaches?
Re: Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
#44Re: Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
#45Re: Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
#46So one question: This "targetting capability" that HIV controllers have, which your goals is to give it to all of us, does it also have any other benefits? Does it also help protect us from other viruses?
Re: Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
#47I don't get it, isn't the point of investing to get the investment back in many multiples? How do you get your investment back if it's a non-profit?
I assume it's a tax dodge of some sort. I'm sure that investments in non-profits can be offset against capital gains (or something like that). I'm not an investor and this isn't tax advice!
Re: Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
#48This is a really interesting project. I have so many questions and it seems others too. It would be great to do an AMA on Reddit or something. So one question: This "targetting capability" that HIV controllers have, which your goals is to give it to all of us, does it also have any other benefits? Does it also help protect us from other viruses?
The "targetting capability", definitely does have implications for other types of viruses. While this vaccine focuses on giving the power of HIV controllers to everybody, other controllers do exist. For example, there may be controllers for other viruses like Hepatitis, HPV, Herpes, or even things like other viruses that cause cancer.
Re: Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
#49Does anyone know why this approach is "viewed as a rogue project by the immunology community"? Is it just because it's new, or is there something more fundamental that conflicts with established immunology?
Re: Startup developing HIV/AIDS vaccine is 2nd nonprofit accepted into Y Combinator
#50How does the vaccine train your immune system? My (very limited) understanding of vaccines is that you would normally train the immune system to target these weak spots by creating an antibody that would bind to said weak spot. But from elsewhere on the page, it says that the project isn't working on an antibody approach. What am I missing?